secwatch.observer — SEC 8-K summary
======================================

Issuer:     VYNE Therapeutics Inc. (VYNE)
CIK:        0001566044
Form:       8-K
Filed at:   2022-04-07T23:59:59+00:00
Accession:  0001104659-22-043670
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 4.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VYNE reports positive Phase 1b data for FMX114 in atopic dermatitis; appoints Baker Tilly as auditor after PwC dismissal
--------------------------------------------------------------------------------

- FMX114 showed statistically significant reduction in ADSI score at week 2: -81.4% mean reduction vs -54.3% for vehicle (p=0.004).
- Pruritus reduced 96.4% mean from baseline for FMX114 vs 45.8% for vehicle at week 2.
- Phase 2a safety and efficacy results expected in Q2 2022.
- Audit committee dismissed PwC as auditor effective April 6, 2022; appointed Baker Tilly US, LLP as new auditor.
- PwC's 2021 report included going concern explanatory paragraph due to incurred losses and negative cash flows.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1566044/000110465922043670/0001104659-22-043670-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1566044/000110465922043670/tm228420d7_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-043670

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer